MAAT.PA

MaaT Pharma SA [MAAT.PA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

MAAT.PA Stock Summary

In the News

MAAT.PA Financial details

Company Rating
-
Market Cap
110.12M
Income
-30.23M
Revenue
3.85M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
51
Optionable
No
Shortable
Yes
Earnings
09 Nov 2023
P/E
-4.85
Forward P/E
-
PEG
-0.5
P/S
61.47
P/B
2.51
P/C
-
P/FCF
-6.63
Quick Ratio
4.55
Current Ratio
4.57
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.75
EPS next Y
-
EPS next Q
-
EPS this Y
23.57%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-44.28%
Revenue last 5Y
90.29%
Revenue Q/Q
-38.32%
EPS Q/Q
27.63%
-
-
-
-
SMA20
-1.99%
SMA50
-19.04%
SMA100
-24.52%
Inst Own
-
Inst Trans
-
ROA
-31%
ROE
-42%
ROC
-0.38%
Gross Margin
76%
Oper. Margin
-948%
Profit Margin
-970%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.5-9.9
52W High
-35.78%
52W Low
+44.5%
RSI
43.34
Rel Volume
4.99
Avg Volume
1.49K
Volume
7.43K
Perf Week
-4.3%
Perf Month
-3.34%
Perf Quarter
-22.73%
Perf Half Y
-22.31%
-
-
-
-
Beta
0.248
-
-
Volatility
0.05%, 0.21%
Prev Close
-0.69%
Price
5.78
Change
-1.7%

Something similar

Top by Market Cap
BRK-B
M&M.NS
LLY.DE
GOOGL
TSLA
Same Sector
MRMD
ORP.PA
6095.T
BWV
ATRS
Same Price Range
600866.SS
600775.SS
EPRX.TO
002893.SZ
OGCP
Similar Market Cap
KMDVX
ASAI.ST
RAAAX
STS.L
HXEM.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 1.49K
  • Market Capitalization 110.12M
  • Employee 51
  • CEO Mr. Herve Affagard
  • Headquarters Lyon,FR
  • IPO Date 2021-11-08
  • Website https://www.maatpharma.com

MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.